The Filing Desk

Oramed Pharmaceuticals vs Rani Therapeutics

Oramed Pharmaceuticals ORMP · Rani Therapeutics RANI · Pharmaceuticals

Oramed Pharmaceuticals reported revenue of $2 million in fiscal 2025, 1.2 times Rani Therapeutics' $2 million in fiscal 2025. Oramed Pharmaceuticals had an operating margin of -754.4%, against -2346.0% at Rani Therapeutics. Free cash flow was −$9 million at Oramed Pharmaceuticals and −$19 million at Rani Therapeutics.

Side by side

Oramed PharmaceuticalsRani Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$2M
Revenue growth—58.9%
Revenue growth a year, last 5 years−5.8%26.2%
Gross margin0.7%—
Operating margin−754.4%−2,346.0%
Net margin3,202.5%−1,817.1%
Free cash flow−$9M−$19M
Free cash flow margin−457.7%−1,151.4%
Return on capital—−127.1%
Net debt to EBITDA——
Dividends and buybacks$5M$0M
Change in diluted share count3.8%132.3%
Last close$3.69$0.58
P/E at the last close1.1×—
Insider trades, last 12 monthssold $941,874bought $50,040, sold $301
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Oramed PharmaceuticalsRani Therapeutics
Operating margin
Percent of revenue
Oramed PharmaceuticalsRani Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Oramed PharmaceuticalsRani Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Oramed Pharmaceuticals and Rani Therapeutics pages.